Interviews - Sarepta Therapeutics (SRPT) had a tumultous year, reaching an all-time high of $55.00 last October before tumbling to lows under $13.00 when the U.S. FDA suggested that the company would need to … Continue Reading
Interviews - In an exclusive PropThink interview with ARIAD Pharmaceuticals (NASDAQ:ARIA), CEO Harvey J. Berger discusses the company’s lead product, ponatinib, a potential treatment for intolerant Chronic … Continue Reading
Interviews - With Orphan Drug status and a largely-unmet medical need for its primary indication, ADVENTRX Pharmaceuticals (AMEX:ANX) expects its lead candidate, ANX-188, to be the company’s … Continue Reading
You're all done! We've sent you a confirmation email that includes a verification link. To access the page you're interested in, check your email inbox(including spam folder) and click the verification link.